We further demonstrated that inhibition of mTOR/PI3K, G2M checkpoint, or the glycolysis pathway through NAMPT inhibition had potent in vitro anti-leukemic activity in human and murine T-ALL cell lines, and inhibitors of G2M checkpoint and NAMPT were effective in human PDX-expanded T-ALL samples of different molecular subtypes. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.